Research Projects & Grants

Other Research

  • Primary Investigator. "Efficacy, safety, and pharmacokinetics of vericiguat in pediatric participants with heart failure due to left ventricular systolic dysfunction." Phase 2/3 adaptive randomized, placebo-controlled, parallel-group, multisite, double-blind study of vericiguat in pediatric participants with HF due to LV systolic dysfunction consistent with dilated cardiomyopathy and NT-proBNP level between 500 and 6000 pg/mL within 30days before randomization. (05/2022 - Present)
  • Participation on national committee: ACTION Network committee for VAD De-escalation. Multicenter committee working to improve VAD patient de-escalation of ICU care, identifying barriers to discharge with the ultimate goal to improve patient rehab and quality of life. (02/2022 - Present)
  • Participation on national committee: Pediatric Heart Transplant Society, Committee on Standardization of Care.  Multicenter collaborative to create harmonized protocols for pediatric heart transplant surveillance for rejection, with an ultimate goal of identifying the safest, most cost-effective and safe protocol for our transplanted patients. (01/2022 - Present)
  • Primary Investigator. "Efficacy, safety, and pharmacokinetics of vericiguat in pediatric participants with heart failure due to left ventricular systolic dysfunction." Phase 2/3 adaptive randomized, placebo-controlled, parallel-group, multisite, double-blind study of vericiguat in pediatric participants with HF due to LV systolic dysfunction consistent with dilated cardiomyopathy and NT-proBNP level between 500 and 6000 pg/mL within 30days before randomization. (05/2022 - Present)
  • Participation on national committee: ACTION Network committee for VAD De-escalation. Multicenter committee working to improve VAD patient de-escalation of ICU care, identifying barriers to discharge with the ultimate goal to improve patient rehab and quality of life. (02/2022 - Present)
  • Participation on national committee: Pediatric Heart Transplant Society, Committee on Standardization of Care.  Multicenter collaborative to create harmonized protocols for pediatric heart transplant surveillance for rejection, with an ultimate goal of identifying the safest, most cost-effective and safe protocol for our transplanted patients. (01/2022 - Present)
  • Primary Investigator. "Efficacy, safety, and pharmacokinetics of vericiguat in pediatric participants with heart failure due to left ventricular systolic dysfunction." Phase 2/3 adaptive randomized, placebo-controlled, parallel-group, multisite, double-blind study of vericiguat in pediatric participants with HF due to LV systolic dysfunction consistent with dilated cardiomyopathy and NT-proBNP level between 500 and 6000 pg/mL within 30days before randomization. (05/2022 - Present)
  • Participation on national committee: ACTION Network committee for VAD De-escalation. Multicenter committee working to improve VAD patient de-escalation of ICU care, identifying barriers to discharge with the ultimate goal to improve patient rehab and quality of life. (02/2022 - Present)
  • Participation on national committee: Pediatric Heart Transplant Society, Committee on Standardization of Care.  Multicenter collaborative to create harmonized protocols for pediatric heart transplant surveillance for rejection, with an ultimate goal of identifying the safest, most cost-effective and safe protocol for our transplanted patients. (01/2022 - Present)